{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:30:44Z","timestamp":1793813444465,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82303875"],"award-info":[{"award-number":["No.82303875"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82303879"],"award-info":[{"award-number":["No.82303879"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","award":["No. 5010-2023001"],"award-info":[{"award-number":["No. 5010-2023001"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Committee","doi-asserted-by":"publisher","award":["JCYJ20250604143712016"],"award-info":[{"award-number":["JCYJ20250604143712016"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024A1515012581"],"award-info":[{"award-number":["2024A1515012581"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2024ZD0520400"],"award-info":[{"award-number":["2024ZD0520400"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2024ZD0520402"],"award-info":[{"award-number":["2024ZD0520402"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jhepr.2026.101995","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:18:12Z","timestamp":1786634292000},"page":"101995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic treatment patterns and clinical outcomes in hepatocellular carcinoma: A multicenter real-world study from China (STAR-HCC)"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-3288","authenticated-orcid":false,"given":"Benyi","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengting","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renguo","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meishi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghe","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongce","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101995_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhepr.2026.101995_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jhepr.2026.101995_bib3","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101995_bib4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101995_bib5","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101995_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000530495","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)","volume":"12","author":"Zhou","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101995_bib7","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101995_bib8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.jhepr.2026.101995_bib9","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2026.101995_bib10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101995_bib11","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101995_bib12","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101995_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101995_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101995_bib15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101995_bib16","first-page":"498","article-title":"Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians","volume":"75","author":"Moris","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhepr.2026.101995_bib17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101995_bib18","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.annonc.2025.05.542","volume":"36","author":"Dong","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.101995_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"Suppl 17","key":"10.1016\/j.jhepr.2026.101995_bib20","volume":"44","author":"Abou-Alfa","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101995_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101995_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2468-1253(24)00247-4","article-title":"Combination locoregional and systemic therapies in hepatocellular carcinoma","volume":"10","author":"Zhong","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101995_bib23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1159\/000547981","article-title":"Real-world treatment patterns and clinical outcomes in patients with unresectable hepatocellular carcinoma: results from the OREIOS study","volume":"15","author":"Chan","year":"2026","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101995_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000546862","article-title":"A newly launched nationwide database revealed real-world evidence on systemic therapy for unresectable hepatocellular carcinoma in Japan: Hepatoma Registry of Integrating and Aggregating Electronic Health Record (HERITAGE)","volume":"15","author":"Asaoka","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101995_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.51665","article-title":"Treatment patterns and survival outcomes among patients with hepatocellular carcinoma","volume":"8","author":"Lau-Min","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhepr.2026.101995_bib26","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005\u201320: an analysis of national mortality surveillance data","volume":"8","author":"Qi","year":"2023","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.jhepr.2026.101995_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0330633","article-title":"Epidemiological trends and projections to 2035 of hepatitis B burden in China, 1990\u20132021","volume":"20","author":"Qi","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2026.101995_bib28","first-page":"779","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101995_bib29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101995_bib30","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101995_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2026.101995_bib32","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDe2400011","article-title":"Reflecting the real world of cancer care \u2014 the impact of broadening trial eligibility","volume":"3","author":"Ramaswami","year":"2024","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.jhepr.2026.101995_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.12119","article-title":"Are observational, real-world studies suitable to make cancer treatment recommendations?","volume":"3","author":"Banerjee","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhepr.2026.101995_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/liv.14864","article-title":"Real-world evidence in hepatocellular carcinoma","volume":"41","author":"Mospan","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101995_bib35","first-page":"127","article-title":"Real-world study of systemic treatment after first-line atezolizumab plus bevacizumab for hepatocellular carcinoma in Asia-Pacific countries","volume":"14","author":"Lee","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101995_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102622","volume":"72","author":"Jin","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jhepr.2026.101995_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000523849","article-title":"Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with unresectable, advanced hepatocellular carcinoma: a real-world, multicenter, retrospective study","volume":"11","author":"Xia","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101995_bib38","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101995_bib39","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S2468-1253(25)00059-7","article-title":"Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial","volume":"10","author":"Shi","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101995_bib40","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101995_bib41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(25)00190-1","article-title":"Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial","volume":"26","author":"Zhou","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101995_bib42","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jhepr.2026.101995_bib43","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.2025.43.16_suppl.4095","article-title":"LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma","volume":"43","author":"Finn","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101995_bib44","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:41:18Z","timestamp":1793810478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926002661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2589555926002661"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101995","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic treatment patterns and clinical outcomes in hepatocellular carcinoma: A multicenter real-world study from China (STAR-HCC)","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101995"}}